The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease

Journal of Internal Medicine

Volumn 275, Issue 4, 2014, Pages 418-427

  Li, X ^a   Li, T Q ^a   Andreasen, N ^a   Wiberg, M K ^a   Westman, E ^a   Wahlund, L O ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alzheimer's disease (AD); Cerebrospinal fluid biomarkers; Diffusion tensor imaging (DTI); Fractional anisotropy (FA); Grey matter (GM); Mean diffusivity (MD)

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN; THREONINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; BRAIN SIZE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEFAULT MODE NETWORK; DIFFUSION TENSOR IMAGING; FEMALE; FRACTIONAL ANISOTROPY; GRAY MATTER; HUMAN; INFERIOR TEMPORAL GYRUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPATHOLOGY; OCCIPITAL CORTEX; PARAHIPPOCAMPAL GYRUS; PRECUNEUS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; VOXEL BASED MORPHOMETRY; WHITE MATTER;

ALZHEIMER'S DISEASE (AD); CEREBROSPINAL FLUID BIOMARKERS; DIFFUSION TENSOR IMAGING (DTI); FRACTIONAL ANISOTROPY (FA); GREY MATTER (GM); MEAN DIFFUSIVITY (MD);

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; BRAIN; CROSS-SECTIONAL STUDIES; DIFFUSION TENSOR IMAGING; DISEASE PROGRESSION; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TAU PROTEINS; THREONINE;

EID: 84897022313     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12164     Document Type: Article

References (47)

1. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006; 368: 387-403.
2. Morris JC, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 2001; 17: 101-118.
3. Tapiola T, Alafuzoff I, Herukka S-K et al. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009; 66: 382-389.
4. Ibach B, Binder H, Dragon M et al. Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample. Neurobiol Aging 2006; 27: 1202-1211.
5. Sunderland T, Linker G, Mirza N et al. Tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003; 289: 2094-2103.
6. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG. Aging, memory, and mild cognitive impairment. Int Psychogeriatr 1997; 9: 65-69.
7. Reisberg B, Gauthier S. Current evidence for subjective cognitive impairment (SCI) as the pre-mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer's disease. Int Psychogeriatr 2008; 20: 1-16.
8. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-234.
9. Mattsson N, Zetterberg H, Hansson O et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302: 385-393.
10. Anand R, Kaushal A, Wani WY, Gill KD. Road to Alzheimer's disease: the pathomechanism underlying. Pathobiology 2012; 79: 55-71.
11. Li T-Q, Wahlund L-O. The search for neuroimaging biomarkers of Alzheimer's disease with advanced MRI techniques. Acta Radiol 2011; 52: 211-222.
12. Devanand DP, Pradhaban G, Liu X et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology 2007; 68: 828-836.
13. Liu Y, Paajanen T, Zhang Y et al. Analysis of regional MRI volumes and thicknesses as predictors of conversion from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging 2010; 31: 1375-1385.
14. Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol Aging 2004; 25: 5-18.
15. Sexton CE, Kalu UG, Filippini N, Mackay CE, Ebmeier KP. A meta-analysis of diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2011; 32: 2322.e5-18.
16. Chua TC, Wen W, Slavin MJ, Sachdev PS. Diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease: a review. Curr Opin Neurol 2008; 21: 83-92.
17. Müller MJ, Greverus D, Weibrich C et al. Diagnostic utility of hippocampal size and mean diffusivity in amnestic MCI. Neurobiol Aging 2007; 28: 398-403.
18. Cherubini A, Péran P, Caltagirone C, Sabatini U, Spalletta G. Aging of subcortical nuclei: microstructural, mineralization and atrophy modifications measured in vivo using MRI. Neuroimage 2009; 48: 29-36.
19. Müller MJ, Mazanek M, Weibrich C, Dellani PR, Stoeter P, Fellgiebel A. Distribution characteristics, reproducibility, and precision of region of interest-based hippocampal diffusion tensor imaging measuresAJNR Am J Neuroradiol 2006; 27: 440-446.
20. Cherubini A, Péran P, Spoletini I et al. Combined volumetry and DTI in subcortical structures of mild cognitive impairment and Alzheimer's disease patients. J Alzheimers Dis 2010; 19: 1273-1282.
21. Wahlund L-O, Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 2003; 339: 99-102.
22. Amlien IK, Fjell AM, Walhovd KB et al. Mild cognitive impairment: cerebrospinal fluid tau biomarker pathologic levels and longitudinal changes in white matter integrity. Radiology 2013; 266: 295-303.
23. Buckner RL, Snyder AZ, Shannon BJ et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005; 25: 7709-7717.
24. Price JL, Morris JC. Tangles and plaques in nondemented aging and 'preclinical' Alzheimer's disease. Ann Neurol 1999; 45: 358-368.
25. Li X, Li T-Q, Andreasen N, Wiberg MK, Westman E, Wahlund L-O. Ratio of Aβ42/P-tau(181p) in CSF is associated with aberrant default mode network in AD. Sci Rep 2013; 3: 1339.
26. Winblad B, Palmer K, Kivipelto M et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the international working group on mild cognitive impairment. J Intern Med 2004; 256: 240-246.
27. Andreasen N, Hesse C, Davidsson P et al. Cerebrospinal fluid β-amyloid (1-42) in Alzheimer disease: differences between early-and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999; 56: 673-680.
28. Vandermeeren M, Mercken M, Vanmechelen E et al. Detection of proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993; 61: 1828-1834.
29. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Andreasen N, Blennow K. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000; 285: 49-52.
30. Simmons A, Westman E, Muehlboeck S et al. MRI measures of Alzheimer's disease and the AddNeuroMed study. Ann N Y Acad Sci 2009; 1180: 47-55.
31. Simmons A, Westman E, Muehlboeck S et al. The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. Int J Geriatr Psychiatry 2011; 26: 75-82.
32. Westman E, Aguilar C, Muehlboeck J-S, Simmons A. Regional magnetic resonance imaging measures for multivariate analysis in Alzheimer's disease and mild cognitive impairment. Brain Topogr 2013; 26: 9-23.
33. Sperling RA, Aisen PS, Beckett LA et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the national institute on aging and the Alzheimer's association workgroup. Alzheimers Dement 2011; 7: 280-292.
34. Seppälä TT, Nerg O, Koivisto AM et al. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology 2012; 78: 1568-1575.
35. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003; 2: 605-613.
36. Visser PJ, Verhey F, Knol DL et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009; 8: 619-627.
37. Herukka S-K, Hallikainen M, Soininen H, Pirttilä T. CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005; 64: 1294-1297.
38. Herukka S, Pennanen C, Soininen H, Pirttilä T. CSF Aβ42, tau and phosphorylated tau correlate with medial temporal lobe atrophy. J Alzheimers Dis 2008; 14: 51-57.
39. Tosun D, Schuff N, Truran-Sacrey D et al. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiol Aging 2010; 31: 1340-1354.
40. Hampel H, Bürger K, Pruessner JC et al. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol 2005; 62: 770-773.
41. Oishi K, Mielke MM, Albert M, Lyketsos CG, Mori S. DTI Analyses and clinical applications in Alzheimer's disease. J Alzheimers Dis 2011; 26: 287-296.
42. Fellgiebel A, Wille P, Müller MJ et al. Ultrastructural hippocampal and white matter alterations in mild cognitive impairment: a diffusion tensor imaging study. Dement Geriatr Cogn Disord 2004; 18: 101-108.
43. Stenset V, Bjørnerud A, Fjell AM et al. Cingulum fiber diffusivity and CSF T-tau in patients with subjective and mild cognitive impairment. Neurobiol Aging 2011; 32: 581-589.
44. Bendlin BB, Carlsson CM, Johnson SC et al. CSF T-Tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimer's disease. PLoS ONE 2012; 7: e37720.
45. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc Natl Acad Sci U S A 2001; 98: 676-682.
46. Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci 2008; 1124: 1-38.
47. Jack CR, Knopman DS, Jagust WJ et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119-128.